Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose Ranging Study of PepGNP-COVID19 as a Booster Dose
NCT07183709Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2026
- Primary completion
- Oct 2026
- Modality
- Peptides, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of PepGNP-COVID19 in coronavirus disease 2019 (COVID-19) (3 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Proportion of participants experiencing Abnormal Clinical Safety Laboratory Adverse Events at 15 days, Proportion of participants experiencing Adverse Events of Special Interest at 181 days and 8 more. Started Feb 2026; status: completed.
02
Drugs
PepGNP-COVID19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07183709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07183709.